Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Tenofovir alafenamide-Emtricitabine Descovy
Tenofovir DF-Emtricitabine Truvada and Multiple Generics
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Rilpivirine EdurantSelf-StudyKey Populations
You are just a few steps away from free CE credits!
Sign in or Register
A free account is required.
Study the Material
An entire Cc section, or just a few topics at a time.
Take the CE Quiz
5 questions covering the topics in each Cc section.
Claim CE Credit
Free CNE and Free CME available!
- Lesson 6 Overview
HIV-2 Infection - 0%Topic 1
BackgroundActivities- 0%Topic 2
HIV-2 EpidemiologyActivities- 0%Topic 3
Pathogenesis, Transmission, and Natural History of HIV-2Activities- 0%Topic 4
2014 Surveillance Case Definition for HIV-2 InfectionActivities- 0%Topic 5
Diagnostic Testing for HIV-2Activities- 0%Topic 6
Antiretroviral Susceptibility and ResistanceActivities- 0%Topic 7
HIV-2 Treatment StudiesActivities- 0%Topic 8
HIV-2 Treatment RecommendationsHIV-2 Infection Overview
About this Lesson
Last Updated: February 3rd, 2025CNE/CME Continuing Education
This lesson qualifies for:- 1 CME AMA PRA Category 1 Credit™, or
- 1 CNE contact hour and 1 CE contact hour (qualifies for pharmacology CE for advanced practice nurses)
CNE and CME Origination: September 17th, 2018CNE and CME Review: September 1st, 2023CNE and CME Expiration: August 31st, 2026 (3rd Edition)
View CE NoticesSteps to Acquire CE for this Lesson:
3Print CE Certificate
Obtain proof of CE3rd Edition
This is a substantial revision of the original Lesson. The previous edition was titled HIV-2 Infection and available until September 1st, 2023.Learning Objectives
- Contrast HIV-2 and HIV-1 epidemiology, natural history, and pathogenesis
- Describe diagnostic testing for HIV-2
- Summarize susceptibility of HIV-2 to antiretroviral medications
- Discuss antiretroviral treatment recommendations for persons with HIV-2
- Explain challenges with monitoring after starting antiretroviral therapy for HIV-2
Lesson Contributors
Authors
David H. Spach, MDDavid H. Spach, MD
Professor of Medicine
Division of Allergy & Infectious Diseases
University of WashingtonDisclosures:NoneJehan Z. Budak, MDJehan Z. Budak, MD
Associate Professor of Medicine
Division of Allergy & Infectious Diseases
University of WashingtonDisclosures:NoneReviewers
Geoffrey S. Gottlieb, MD, PhDGeoffrey S. Gottlieb, MD, PhD
Professor of Medicine
Division of Allergy & Infectious Diseases
Adjunct Professor of Global Health
Medical Director, Environmental Health & Safety Department
Center for Emerging & Re-Emerging Infectious Diseases
University of WashingtonDisclosures:Grants to Institution: Abbot Molecular Diagnostics, Alere Technologies, Bristol-Myers Squibb, Ceres Corporation, Gilead Sciences, Janssen Pharmaceuticals, Merck & Co. Inc, Roche Molecular Systems, THERA Technologies/TaiMed Biologics, Inc., and ViiV Healthcare.The relevant financial relationship was mitigated.Lesson Plan
Quick Reference View
A single document for easy access to every topic in the self-study modules.
PDF version also available.
No sign-in required for Quick Reference
Question Bank
Interactive board-review style questions about Epidemiology of HIV.
CNE/CME CME+MOC credits and CNE contact hours available.
Requires sign-in for CE credit or Certificates
Funded byHealth Resources and Services Administration (HRSA)Created at University of WashingtonAn AETC ProgramPart of IDEA PlatformCME provided byUniversity of Alabama BirminghamCNE approved byOregon Nurses AssociationCopyright © 2025 National HIV CurriculumThe Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS) provided financial support for this website. The award provided 100% of total costs and totaled $1,172,994. The contents are those of the author. They may not reflect the policies of HRSA, HHS, or the U.S. Government.Since you've received 80% or better on this quiz, you may claim continuing education credit.
You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.
Current Version: nhivc-master-d52d2330-2025-09-05-201745 - 0%Topic 2